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Abstract
Background: Transforming growth factor beta (TGF-b) has critical roles in regulating cell growth, differentiation, apoptosis,
invasion and epithelial-mesenchymal transition (EMT) of various cancer cells. TGF-b-induced EMT is an important step
during carcinoma progression to invasion state. Thioredoxin binding protein-2 (TBP-2, also called Txnip or VDUP1) is
downregulated in various types of human cancer, and its deficiency results in the earlier onset of cancer. However, it
remains unclear how TBP-2 suppresses the invasion and metastasis of cancer.
Principal Findings: In this study, we demonstrated that TBP-2 deficiency increases the transcriptional activity in response to
TGF-b and also enhances TGF-b-induced Smad2 phosphorylation levels. Knockdown of TBP-2 augmented the TGF-b-
responsive expression of Snail and Slug, transcriptional factors related to TGF-b-mediated induction of EMT, and promoted
TGF-b-induced spindle-like morphology consistent with the depletion of E-Cadherin in A549 cells.
Conclusions/Significance: Our results indicate that TBP-2 deficiency enhances TGF-b signaling and promotes TGF-b-
induced EMT. The control of TGF-b-induced EMT is critical for the inhibition of the invasion and metastasis. Thus TBP-2, as a
novel regulatory molecule of TGF-b signaling, is likely to be a prognostic indicator or a potential therapeutic target for
preventing tumor progression.
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Introduction
Transforming growth factor-b (TGF-b) has dual functions in
cancer [1]. TGF-b acts as a tumor suppressor in the early stage of
tumor development, and contradictorily, promotes the invasion
and metastasis of tumor cells in the late stage. Recently, many
studies have shown that TGF-b promotes cancer progression by
inducing Epithelial-mesenchymal transition (EMT), which is a
crucial process to acquire the ability to execute the invasion-
metastasis steps of cancer [2,3]. TGF-b induces the expression of
several transcription factors driven to EMT [4], including Snail/
SNAI1 [5] and Slug/SNAI2 [6], which act directly or indirectly as
a repressor of E-Cadherin. The loss of E-Cadherin is a
fundamental event in EMT [7,8].
Thioredoxin binding protein-2 (TBP-2), also known as thir-
edoxin interacting protein (Txnip) [9] or Vitamin D3 upregulated
protein 1 (VDUP1) [10], has been identified as a negative
regulator of thioredoxin (TRX) [11] and is mainly localized in
nucleus [12]. TBP-2 is a member of a-arrestin protein family, and
contains two PPxY motifs, which are known to interact with WW
domain-containing proteins including Nedd4 family of E3
ubiquitin ligases [13,14]. TBP-2 has a variety of biological
functions in cell proliferation [15], cell apoptosis [16], immune
response [17,18,19], glucose and lipid metabolism
[9,20,21,22,23,24].
There is the growing evidence that TBP-2 plays as a suppressor
of cancer. TBP-2 is downregulated in various human cancer cells
[25,26]. TBP-2 overexpression inhibits proliferation via cell cycle
arrest [12,27,28,29] and promotes apoptosis [30]. In human T cell
lymphocyte virus type 1 (HTLV-I)- infected T cells, TBP-2
regulates cell growth and its expression is associated with
responsiveness to IL-2-dependent growth [31], and plays a key
role in glucocorticoid-induced cell death [32]. In vivo studies, TBP-
2 overexpression suppressed tumor growth and metastasis of the
transplanted tumor. Point mutation or knock out of TBP-2 gene in
mice show the higher incidence of hepatocellular carcinoma
[33,34]. TBP-2 knock out mice also shows the earlier onset of N-
butyl-N- (4-hydroxybutyl) nitrosamine (BBN)-induced bladder
carcinoma [35].
These results collectively support that TBP-2 deficiency
contributes to the progression and metastasis of cancer, however,
detail mechanisms of TBP-2 in this process has not been
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39900TBP-2 Deficiency Enhances TGF-b Signaling
PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e39900sufficiently elucidated. In the late stage of cancer cells, TBP-2
expression is downregulated and TGF-b elicits cancer malignancy
driving EMT. This correlation provides the hypothesis that TBP-2
regulates TGF-b-associated cancer development in the late stage.
In the present study, we examined the role of TBP-2 in TGF-b
signaling. TBP-2 deficiency increased TGF-b signaling by
enhancing Smad2 phosphorylation levels, and upregulated TGF-
b-induced expression of Snail or Slug, resulting in acceleration of
TGF-b-driven EMT. These findings show a novel function of
TBP-2, as a regulator of TGF-b signaling, and provide new
insights to the mechanisms of TGF-b-induced EMT.
Results
TBP-2 Deficiency Enhances Transcriptional Activity of
TGF-b Signaling
To investigate the function of TBP-2 in TGF-b signaling, we
performed promoter assay using 96CAGA-Luc (TGF-b-respon-
sive promoter-reporter), which is the most frequently used reporter
system for TGF-b/Smad signal transduction, in WT (Wild Type:
TBP-2
+/+) mouse embryonic fibroblasts (MEFs) and TBP-2
2/2
MEFs. The results showed that transcriptional activity in response
to TGF-b is enhanced in TBP-2
2/2 MEFs compared with WT
MEFs (Fig. 1A). The efficiency of TBP-2 knockdown in A549 and
MDA-MB-231 cells was confirmed by real-time RT-PCR (Fig. 1B).
All experiments with TBP-2 siRNA were done according to the
same protocol. Knockdown of TBP-2 also resulted in enhancing
TGF-b-induced transcriptional activity in A549, MDA-MB-231
(Fig. 1C) and 253J (data not shown) cell lines.
TBP-2 Deficiency Increases the mRNA Expression of TGF-
b-targeted Genes
To further examine that TBP-2 regulates the expression of
TGF-b-target genes, plasminogen activator inhibitor (PAI)-1 and
Smad7, well known TGF-b-targeted genes, were quantified by
real-time RT-PCR. TGF-b-mediated induction of PAI-1 and
Smad7 is increased in TBP-2
2/2 MEFs (Fig. 2A), as well as A549
and MDA-MB-231 cells under the condition of TBP-2 knockdown
(Fig. 2B).
TBP-2 Deficiency Increases TGF-b-mediated
Phosphorylation of Smad2
Next, we analyzed the level of TGF-b-mediated phosphoryla-
tion of Smad2 in WT and TBP-2
2/2 MEFs by the western blot
analyses. The phospho-Smad2 protein level was declined at 20
hour-TGF-b stimulation in WT MEFs, but was continuously
elevated in TBP-2
2/2 MEFs (Fig. 3A). Similarly, phospho-Smad2
levels were enhanced with TGF-b stimulation for 12, 24 and 36
hours in TBP-2 knockdown-A549 cells (Fig. 3B). In addition, total
Smad2 protein levels went down for 4 hours, responding to TGF-b
stimulation, but were unchanged between 4 to 20 hours in WT
MEFs, whereas no significant differences from 0 to 20 hours with
TGF-b stimulation in TBP-2
2/2 MEFs (Fig. 3A).
TBP-2 Deficiency Enhances the Induction of Snail and
Slug by TGF-b
TGF-b induces the expression of transcriptional factors involved
in EMT, including Snail and Slug. As the induction of Snail or
Slug is a crucial step for EMT, the effect of TBP-2 knockdown on
Figure 1. Deficiency of TBP-2 enhances the transcriptional activity of TGF-b signaling. (A) Effect of TBP-2 deficiency on the transcriptional
activity of TGF-b was examined using 96CAGA-MLP-Luc, TGF-b responsive luciferase reporter, in WT (Wild Type: TBP-2
+/+) and TBP-2
2/2 MEFs with or
without TGF-b (0.5 ng/ml). (B) The efficiency of TBP-2 knockdown by TBP-2 siRNA and negative control (N.C.) in A549 and MDA-MB-231 cells was
determined by quantitative real-time PCR at 36 hours after transfection. (C) Effect of TBP-2 knockdown on the transcriptional activity of TGF-b was
examined using 96CAGA-MLP-Luc in A549 and MDA-MB-231 cells with or without TGF-b. N.C. means negative control. The error bars show mean 6
SD.
*P,0.05,
**P,0.01,
***P,0.001, versus control (t-test).
doi:10.1371/journal.pone.0039900.g001
Figure 2. Deficiency of TBP-2 upregulates mRNA of TGF-b
targeted genes. (A) TGF-b-induced mRNA expression of PAI-1 or
Smad7, TGF-b targeted genes, in WT and TBP-2
2/2 MEFs was
determined by quantitative real-time PCR. MEFs were cultured in the
presence or absence of TGF-b (0.5 ng/ml) for 8 hours. (B) The effects of
TBP-2 knockdown for TGF-b-induced mRNA expression of PAI-1 or
Smad7 in A549 cells and MDA-MB-231 cells were determined by
quantitative real-time PCR. A549 cells and MDA-MB-231 cells were
cultured in the presence or absence of TGF-b (2.5 ng/ml for 6 hours and
1 ng/ml for 12 hours, respectively). N.C. means negative control. The
error bars show mean 6 SD. **P,0.01, N.S.: not significant.
doi:10.1371/journal.pone.0039900.g002
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time RT-PCR. The results showed that the TGF-b-responsive
expression of Snail and Slug was enhanced with TGF-b
stimulation for 6, 12 and 22 hours in A549 cells under the
condition of TBP-2 knockdown (Fig. 4).
TBP-2 Deficiency Promotes TGF-b-induced EMT
Then, we evaluated the effects of TBP-2 knockdown in TGF-b-
induced EMT. Knockdown of TBP-2 promoted TGF-b-induced
morphological changes in A549 (Fig. 5) and 253J cells (data not
shown). In the presence of 2.5 ng/ml TGF-b for 24 or 36 hours,
TGF-b-driven spindle-like morphology was significantly observed
in TBP-2 knockdown-A549 cells. To quantify the morphological
changes, we measured the length of the longest diagonal line of
each cell. TBP-2 knockdown-cells with TGF-b stimulation
significantly lengthened more than control cells (Fig. S1).
Consistently, the depletion of E-Cadherin, an epithelial marker,
was quickened, and similarly the induction of vimentin, a
mesenchymal marker, was elevated in TBP-2 knockdown-A549
cells (Fig. 6). These results indicate that TBP-2 deficiency
accelerates the TGF-b-driven EMT phenotype.
Discussion
In this study, we demonstrated that deficiency of TBP-2
increases TGF-b-responsive transcriptional activity and upregu-
lates Smad2 phosphorylation levels, resulting in the acceleration of
TGF-b-induced EMT.
TBP-2 deficiency contributes to upregulate transcriptional
activities for several stimuli or ligands. We or other groups
reported that peroxisome proliferator activated receptor (PPAR)
or insulin target genes are upregulated in TBP-2
2/2 mice, and
that TBP-2 negatively regulates PPAR transcriptional activity
in vitro [23]. TBP-2 deficiency might maintain the level of
transcriptional activities with the imperfection of biological
feedback.
TBP-2 deficiency also results in the enhancement of phosphor-
ylation of signal transducers. Regarding the relationship between
TBP-2 and cell signaling, it was reported that phosphorylation of
ERK is enhanced in TBP-2-KO mice [36] bladders during BBN-
induced bladder carcinogenesis [35]. Our previous study showed
that TBP-2 is a negative regulator of TRX [11], and other group
reported that overexpression of TRX elevates the ERK1/2
phosphorylation levels [37]. These reports suggest that TBP-2
deficiency facilitates TRX activity, resulting in enhancement of the
phosphorylation levels of signal transducer, such as ERK1/2.
However, TBP-2 deficiency did not change the protein levels of
TRX in the presence or absence of TGF-b (data not shown), so
Figure 3. Deficiency of TBP-2 maintains the higher phosphor-
ylation level of Smad2. (A) WT and TBP-2
2/2 MEFs cells were
stimulated with TGF-b (0.5 ng/ml) for the indicated times. p-Smad2,
Smad2 and b-actin were analyzed by Western blot. (B) A549 cells under
the condition of TBP-2 knockdown or not were stimulated with TGF-b
(2.5 ng/ml) for the indicated times. p-Smad2, Smad2 and a-tubulin were
analyzed by Western blot. N.C. means negative control.
doi:10.1371/journal.pone.0039900.g003
Figure 4. Knockdown of TBP-2 promotes Snail and Slug
induction by TGF-b. Induction of Snail (A) or Slug (B) transcription
was examined in A549 cells under the condition of TBP-2 knockdown
(black bars) or not (gray bars) cultured with TGF-b (2.5 ng/ml) for the
indicated times. Snail or Slug mRNA were determined by quantitative
real-time PCR. N.C. means negative control. The error bars show mean
6 SD. *P,0.05, **P,0.01, ***P,0.001, versus control (t-test).
doi:10.1371/journal.pone.0039900.g004
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(TBP-2) or negative control siRNA (N.C.) were cultured in the presence of TGF-b (2.5 ng/ml) for 0, 12, 24 and 36 hours. Photos were taken at the
indicated times.
doi:10.1371/journal.pone.0039900.g005
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TBP-2.
The re-expression of TBP-2 using expression vector in TBP-
2
2/2 MEFs failed to rescue the knock out effects of TBP-2 on the
CAGA promoter. We also performed the experiments on the
gain-of-function of TBP-2 using expression vector in A549 and
MDA-MB-231 cell lines. The results unexpectedly showed that
the overexpression of TBP-2 did not lead to the opposite of the
loss-of-function results (data not shown). These results might be
caused by the difficulty in controlling the expression level of TBP-
2 within the physiological range. Since TBP-2 is a multifunctional
protein targeting several molecules, the superabundant expression
of TBP-2 might cause unexpected effects, which should be
dissected in our future study.
It has been also reported that TBP-2 deficiency promotes TNF-
a-induced NF-kB activity [34], that TBP-2 inhibits mTOR
activity by binding REDD1 protein [38], and that TBP-2
deficiency enhances the phosphorylation of Akt in response to
insulin [16,24]. The present study shows that TBP-2 deficiency
enhances TGF-b-mediated Smad2 phosphorylation level. These
findings suggest that TBP-2 act as a crucial feedback regulator for
various biological responses. TBP-2 might be essential for protein
phosphatases or protein degradation systems.
TBP-2 deficiency enhanced TGF-b signaling and upregulated
Smad7 expression (Fig. 1 and 2). Smad7, one of inhibitory Smads,
plays an essential role in the negative feedback regulation of TGF-
b signaling [39], however, TBP-2 deficiency enhanced TGF-b-
mediated Smad2 phosphorylation (Fig. 3) irrespective of increasing
Smad7 expression. In the negative feedback of TGF-b signaling,
Smad7 requires to bind to Smad ubiquitin regulatory factor 2
(Smurf2), HECT type E3 ligases containing WW domain [39,40].
Smad7-Smurf2 complex binds to the activated TGF-b receptors,
and induces their degradation [41,42]. In addition, Smurf2 also
decreases the protein levels of Smad2 in response to TGF-b
stimulation. Our results showed that total Smad2 protein levels
went down for 4 hours, responding to TGF-b stimulation in WT
MEFs, but no significant differences in TBP-2
2/2 MEFs. TBP-2
contains two PPxY motifs, which are reported to interact with
WW domain. TBP-2 interacts with Smurf2 in co-immnoprecipita-
tion assay (data not shown), providing the hypothesis that TBP-2 is
required for functions of Smurf2 in the negative feedback of TGF-
b signaling. The significance of TBP-2-Smurf2 interaction has
been entirely unclear and will be examined in detail.
In conclusion, we demonstrated that TBP-2 deficiency enhances
Smad2 phosphorylation level, resulting in acceleration of TGF-b-
driven EMT. Our findings show a novel mechanisms of cancer
suppression associated with TBP-2 and provide new insights into
TGF-b-mediated EMT. TBP-2 is likely to be a prognosis indicator
by monitoring TBP-2 expression in tumor, and a potential
therapeutic target in the inhibition of EMT.
Materials and Methods
Reagents and Antibodies
TGF-b1 was purchased from R&D systems. Stealth small
interfering RNA (siRNA) for TBP-2 (UCAAUUCGAGCAGA-
GACAGACACCC) and a negative control were purchased from
Invitrogen. The antibodies used were as follows: anti-phospho-
Smad2 (Ser465/467) (138D4) and anti-Smad2 (L16D3) antibodies
were purchased from Cell Signaling. Anti-Txnip antibody and
Anti-Vimentin were from MBL. Anti-E-Cadherin antibody was
from Transduction Laboratories. Anti-b-actin antibody was from
Santa Cruz. Anti-a-tubulin antibody was from Sigma.
Cell Culture
Primary wild-type and TBP-2
2/2 mouse embryonic fibroblasts
(MEFs) were generated as previously described [24]. Human lung
adenocarcinoma cell line A549 was obtained from Health Science
Research Bank. Human breast cancer cell line MDA-MB-231 was
from DS Pharma Biomedical. MEFs, A549 and MDA-MB-231
cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) with 10% fetal bovine serum (FBS), 1% penicillin/
streptomycin antibiotics, and 2 mM L-glutamine. The culture was
maintained at 37uC with 5% CO2.
RNA Interference
All knockdown assay using siRNAs were performed with
Lopofectamine 2000 (Invitrogen) according to the manufacturer’s
instruction. The cells were used after 36 hours from transfection.
Transient Transfection and Luciferase Reporter Assay
Cells were transiently transfected with pGL3 96CAGA-MLP-
Luc and pRL-TK (Promega) using TransIT-LT1 (Takara)
according to the manufacturer’s instruction. pRL-TK was used
as a control of the efficiency of transfection. At the same time of
transfection, cells were under the condition of serum deprivation.
After 20 hours of transfection, cells were stimulated with TGF-b
for 20 hours. Luciferase activity was measured with the Dual-
Luciferase reporter system (Promega).
RNA Isolation, RT-PCR and Real-time Quantitative PCR
Total RNAs were extracted using TRIzol (Invitrogen), and were
reverse-transcribed using High-Capacity cDNA Reverse Tran-
scription Kits (Applied Biosystems) according to the manufactur-
er’s instruction. Real-time PCR was performed with Power STBR
Green PCR Master Mix (Applied Biosystems), using b-actin as an
internal control for normalization. Fluorescent detection and data
analyses were performed using ABI 7500 Sequence Detection
System (Applied Biosystems). Primers for PCR analyses were listed
in Table S1.
Figure 6. Knockdown of TBP-2 accelerates TGF-b-driven E-
Cadherin degradation. A549 cells transfected with TBP-2-targeting
siRNA (TBP-2) or negative control siRNA (N.C.) were treated with TGF-b
(2.5 ng/ml) for 0, 12, 24 and 36 hours. E-Cadherin, Vimentin, TBP-2 and
a-tubulin were analyzed by Western blot.
doi:10.1371/journal.pone.0039900.g006
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For western blotting, the cells were lysed in CelLytic M Cell
Lysis Reagent (Sigma-Aldrich) containing a protease inhibitor
cocktail (Roche) and phosphatase inhibitor (Nacalai Tesque). The
lysate were boiled with Laemmli Smaple Buffer (BIO-RAD) at
95uC for 3 minutes. The samples were subjected to SDS-PAGE,
transferred to PVDF membranes, and incubated with primary
antibodies. The membranes were washed and incubated with
horseradish peroxidase-conjugated secondary anti-mouse- or anti-
rabbit-immunoglobulin G (GE Lifesciences). Finally, chemilumi-
nescence was detected using Chemi-Lumi One L kit (Nacalai
Tesque), and luminescence images were analyzed by LAS 3000 or
LAS 4000 (GE Lifesciences).
Supporting Information
Figure S1 The length of the longest diagonal line of
TBP-2 siRNA-A549 and control siRNA-A549 cells in the
presence or absence of TGF-b (2.5 ng/ml for 36 hours).
The length of each cell was calculated from expanded photos (200
cells).
(TIF)
Table S1 Primer sequences for real-time PCR analyses.
(TIFF)
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